Related Experiment Videos
Misoprostol in peptic ulcer disease
1Department of Medicine, Western Infirmary, Glasgow, Scotland.
Prostaglandins
|January 1, 1987
Summary
Misoprostol effectively heals gastric and duodenal ulcers, offering pain relief comparable to cimetidine. This prostaglandin E1 analog demonstrates superior results to placebo, with minimal side effects like diarrhea.
Area of Science:
- Gastroenterology
- Pharmacology
- Internal Medicine
Background:
- Misoprostol, a synthetic prostaglandin E1 (PGE1) analog, possesses antisecretory and cytoprotective properties beneficial for gastric and duodenal mucosa.
- Peptic ulcer disease remains a significant condition requiring effective therapeutic interventions.
Purpose of the Study:
- To evaluate the efficacy and safety of misoprostol in treating benign gastric and active duodenal ulcers.
- To compare misoprostol's effectiveness against placebo and cimetidine in ulcer healing and pain management.
Main Methods:
- Two multicenter, randomized, double-blind, controlled trials in over 900 patients with gastric ulcers.
- Six similar trials in over 2000 patients with duodenal ulcers, comparing various misoprostol doses to placebo or cimetidine.
- Assessment of ulcer healing rates, pain relief, and adverse events.
Main Results:
- Misoprostol (800 mcg daily) significantly improved complete ulcer healing and pain relief compared to placebo.
- Efficacy of misoprostol was comparable to conventional doses of cimetidine.
- Adverse effects were infrequent, with dose-related diarrhea occurring in a small proportion of patients.
Conclusions:
- Misoprostol is an effective treatment for gastric and duodenal ulcers, offering significant healing and pain relief.
- The drug is well-tolerated, with a favorable safety profile compared to placebo and cimetidine.
- Potential benefits include protection against NSAID-induced damage and mitigating smoking's negative impact on ulcer healing.